Cell Therapeutics Begs for Survival
With cash dwindling and currently authorized shares almost depleted, Cell Therapeutics is in danger of bankruptcy unless a majority of shareholders vote to allow the small, money-losing biotech firm to increase the number of company shares to 1.2 billion from its present level of 800 million.
The shareholder vote will be tallied at Cell Therapeutics' annual shareholder meeting on Thursday, Sept. 16. Before that, Cell Therapeutics is scheduled to present at the Rodman & Renshaw investment conference on Tues. Sept. 14.
Since 2005, Cell Therapeutics shares have plunged more than 99.9%, hit again and again by clinical trial blowups and drug approval rejections. The stock closed Friday at 38 cents. The only biotech firms that have caused greater shareholder losses over this time period are no longer in business. The fact that Cell Therapeutics is still alive is somewhat of an unexplainable phenomenon but may be a testament to the quicksilver tongue and wily fund-raising ability of the company's chief executive.Yet Bianco has run out of tricks. He can sell no more stock because the company has no more stock to sell. If Bianco is going to keep the lights on at Cell Therapeutics and continue to pull down his customary multi-million dollar package of salary, bonus, stock options and executive perks, he needs the help of shareholders. Which is why the company is now groveling for the mercy of its shareholders, pleading with them to approve the share-boosting plan: "We all have family or friends who have been struck down by cancer. At CTI, we believe we can make cancer more treatable for many cancer patients by advancing the products in our development pipeline – that is our mission," says a letter signed by Cell Therapeutics' CFO Louis Bianco, the brother of CEO Jim Bianco, and sent to shareholders recently. "We are committed to bringing our drugs to cancer patients, but CTI needs your support," the letter continues. "Your vote can help us make a difference in the potential success of these drugs and in the lives of the patients who could someday benefit from them. Without your voting support, CTI may not be able to continue this research."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV